CA3002520A1 - Compositions contenant un exosome charge d'une proteine, et procedes de preparation et d'administration correspondants - Google Patents

Compositions contenant un exosome charge d'une proteine, et procedes de preparation et d'administration correspondants Download PDF

Info

Publication number
CA3002520A1
CA3002520A1 CA3002520A CA3002520A CA3002520A1 CA 3002520 A1 CA3002520 A1 CA 3002520A1 CA 3002520 A CA3002520 A CA 3002520A CA 3002520 A CA3002520 A CA 3002520A CA 3002520 A1 CA3002520 A1 CA 3002520A1
Authority
CA
Canada
Prior art keywords
protein
exosome
cells
photo
exosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3002520A
Other languages
English (en)
Inventor
Chulhee Choi
Kyungsun CHOI
Seung-Wook RYU
Nambin YIM
Hojun CHOI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilias Biologics Inc
Original Assignee
Cellex Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160126961A external-priority patent/KR101912315B1/ko
Priority claimed from KR1020160126335A external-priority patent/KR101877010B1/ko
Priority claimed from KR1020160126921A external-priority patent/KR101912313B1/ko
Priority claimed from KR1020160127486A external-priority patent/KR101912310B1/ko
Priority claimed from KR1020160132616A external-priority patent/KR101900465B1/ko
Application filed by Cellex Life Sciences Inc filed Critical Cellex Life Sciences Inc
Publication of CA3002520A1 publication Critical patent/CA3002520A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01015—Peroxiredoxin (1.11.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)

Abstract

La présente invention concerne un procédé de production en masse d'un exosome comprenant une protéine cargo, un vecteur permettant de préparer l'exosome, l'exosome comprenant une protéine cargo préparé par le procédé, ainsi qu'un procédé permettant de charger la protéine cargo dans le cytosol en utilisant l'exosome préparé par le procédé. Selon le procédé de préparation d'un exosome comprenant une protéine cargo proposé par la présente invention, l'exosome chargé d'une protéine cargo peut être produit avec un rendement élevé, de sorte qu'il peut être utilisé largement pour le traitement d'une maladie en utilisant l'exosome.
CA3002520A 2016-09-30 2017-09-29 Compositions contenant un exosome charge d'une proteine, et procedes de preparation et d'administration correspondants Pending CA3002520A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
KR1020160126961A KR101912315B1 (ko) 2016-09-30 2016-09-30 Bax 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
KR1020160126335A KR101877010B1 (ko) 2016-09-30 2016-09-30 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR10-2016-0126961 2016-09-30
KR10-2016-0126921 2016-09-30
KR10-2016-0126335 2016-09-30
KR1020160126921A KR101912313B1 (ko) 2016-09-30 2016-09-30 Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
KR10-2016-0127486 2016-10-04
KR1020160127486A KR101912310B1 (ko) 2016-10-04 2016-10-04 페록시레독신 i 또는 ii 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 항산화용 약학적 조성물
KR10-2016-0132616 2016-10-13
KR1020160132616A KR101900465B1 (ko) 2016-10-13 2016-10-13 CRISPR-CAS family를 이용한 게놈 에디팅 툴을 엑소솜으로 전달하는 기술
KR20170018637 2017-02-10
KR10-2017-0018637 2017-02-10
PCT/KR2017/011070 WO2018062973A1 (fr) 2016-09-30 2017-09-29 Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants

Publications (1)

Publication Number Publication Date
CA3002520A1 true CA3002520A1 (fr) 2018-04-05

Family

ID=61760013

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002520A Pending CA3002520A1 (fr) 2016-09-30 2017-09-29 Compositions contenant un exosome charge d'une proteine, et procedes de preparation et d'administration correspondants

Country Status (7)

Country Link
EP (1) EP3356522A4 (fr)
JP (1) JP2019528674A (fr)
CN (1) CN108473973A (fr)
AU (1) AU2017335084B2 (fr)
CA (1) CA3002520A1 (fr)
IL (1) IL259023B (fr)
WO (1) WO2018062973A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307890A1 (fr) * 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Utilisation d'exosomes pour le traitement de maladies
US10709797B2 (en) 2017-08-16 2020-07-14 City University Of Hong Kong Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
WO2019198077A1 (fr) * 2018-04-10 2019-10-17 Brainstorm Cell Therapeutics Ltd. Exosomes spécifiques à un type de cellules et utilisation associée
CN110387416B (zh) * 2018-04-16 2022-06-17 华东理工大学 可控聚合调控功能的纳米金双探针体系及其应用
EP3826603A4 (fr) * 2018-07-24 2022-05-04 Mayo Foundation for Medical Education and Research Compositions et procédés impliquant la transformation de vésicules extracellulaires
CN110885789A (zh) * 2018-09-05 2020-03-17 中国科学院生物物理研究所 高效可控包装內源核酸的工程化外泌体制备及其应用
CN109097336A (zh) * 2018-09-07 2018-12-28 深圳市新仑生物科技有限公司 一种干细胞外泌体、制备方法及应用
JP2022513311A (ja) * 2018-09-21 2022-02-07 シティー・ユニバーシティー・オブ・ホンコン カーゴ積載細胞外小胞
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
KR102125567B1 (ko) 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
CN110669723A (zh) * 2019-11-08 2020-01-10 赵凯 一种基于差速离心法的细胞外泌体提取工艺
EP4084777A4 (fr) * 2019-12-30 2024-02-07 Ilias Biologics Inc. Compositions contenant un exosome portant des inhibiteurs de nf-kb et procédés d'utilisation correspondants
JP2023511271A (ja) 2020-01-13 2023-03-17 カーマイン・セラピューティクス・プライベート・リミテッド 核酸搭載細胞外小胞
US20230211010A1 (en) 2020-02-10 2023-07-06 Exostemtech Co., Ltd. Exosome comprising photocleavable protein, and use thereof
KR102688170B1 (ko) 2020-02-10 2024-07-24 주식회사 엑소스템텍 광 절단성 단백질을 포함하는 엑소좀 및 이의 이용
CN113388584A (zh) * 2020-03-10 2021-09-14 路宝特（南京）环保科技有限公司 一种促进皮肤组织损伤后修复用工程化外泌体的制备方法及其应用
CN115335079A (zh) * 2020-03-31 2022-11-11 伊利亚斯生物制品公司 基于外泌体递送nf-kb抑制剂的用途
CN111905105B (zh) * 2020-07-02 2023-05-05 华南师范大学 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
CN114716548A (zh) 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN113234686A (zh) * 2021-04-28 2021-08-10 大连干细胞与精准医学创新研究院 一种靶蛋白递送载体的制备方法
CN113447658B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒
CN116355858A (zh) * 2023-05-29 2023-06-30 北京大学 一种用于递送CRISPR-Cas9的工程化细胞外囊泡及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
JP4662708B2 (ja) * 2001-08-17 2011-03-30 エクソセラ・エルエルシー エクソゾームにタンパク質を標的化する方法および組成物
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
ES2420973T3 (es) 2007-07-25 2013-08-28 University Of Louisville Research Foundation, Inc. Micro-ARN asociado a exosoma como marcador de diagnóstico
CA2713909C (fr) 2008-02-01 2023-12-12 The General Hospital Corporation Utilisation de microvesicules dans le diagnostic, le pronostic et le traitement de maladies et d'affections medicales
US8431530B2 (en) * 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
JP2012531391A (ja) * 2009-07-02 2012-12-10 アイティーエイチ イミュン セラピー ホールディングス エービー ガンのエキソソーム−ベースの治療
FR2950350B1 (fr) * 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
SG183579A1 (en) * 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2013048185A2 (fr) * 2011-09-30 2013-04-04 한국과학기술원 Procédé de formation d'un nano-agrégat réversible de protéines à l'aide de lumière dans une cellule
WO2013089738A1 (fr) * 2011-12-15 2013-06-20 Morehouse School Of Medicine Compositions et procédés pour l'expression ciblée d'exosomes
KR101433057B1 (ko) * 2012-03-07 2014-09-23 한국과학기술원 빛에 의해 ｒｔｋ 신호전달을 활성화하는 융합단백질 및 그의 용도
ES2662326T5 (es) * 2013-04-12 2021-08-04 Evox Therapeutics Ltd Vesículas de suministro terapéutico
US20160186208A1 (en) * 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN103468642A (zh) * 2013-09-23 2013-12-25 山西大学 一种分离细胞培养基中外泌体的方法
EP3145493B1 (fr) * 2014-05-18 2022-07-27 Children's Medical Center Corporation Procédés et compositions apparentés à des exosomes
WO2016044947A1 (fr) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes utiles pour traiter une maladie de stockage lysosomal
CA2965530A1 (fr) * 2014-11-07 2016-05-12 Wisconsin Alumni Research Foundation Ciblage de vaccins a adn sur les lymphocytes b
JPWO2016143805A1 (ja) * 2015-03-10 2018-02-15 テオリアサイエンス株式会社 膀胱がんの検出方法
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법

Also Published As

Publication number Publication date
EP3356522A4 (fr) 2019-03-27
IL259023B (en) 2022-09-01
AU2017335084B2 (en) 2023-06-29
CN108473973A (zh) 2018-08-31
WO2018062973A1 (fr) 2018-04-05
JP2019528674A (ja) 2019-10-17
IL259023A (en) 2018-07-31
EP3356522A1 (fr) 2018-08-08
AU2017335084A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
CA3002520A1 (fr) Compositions contenant un exosome charge d'une proteine, et procedes de preparation et d'administration correspondants
US11872193B2 (en) Compositions containing protein loaded exosome and methods for preparing and delivering the same
JP7386923B2 (ja) 新型天然タンパク質及びその使用
KR102380324B1 (ko) 헌팅턴병을 치료하기 위한 방법 및 조성물
AU2016258423B8 (en) Production method for exosome comprising cargo protein, and method for transferring cargo protein into cytoplasm by using exosome produced by means of the production method
JP7423522B2 (ja) 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
KR102674612B1 (ko) Tau 조절제 및 그것의 전달을 위한 방법 및 조성물
BR112020008704A2 (pt) edição de genes de células primárias
JP2021521819A (ja) 改変されたミトコンドリアおよびその使用
JP2022512579A (ja) タウタンパク質のモジュレーションのための方法および組成物
Ben et al. Construction of exosomes that overexpress CD47 and evaluation of their immune escape
US20160032244A1 (en) Method of inducing cellular differentiation using the Notch3 receptor intracellular domain
US20240189247A1 (en) Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules
EP4104860A1 (fr) Exosome comprenant une protéine photoclivable, et utilisation associée
WO2012052594A2 (fr) Utilisation de dlk1 en tant qu'inhibiteur de l'angiogenèse

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507

EEER Examination request

Effective date: 20210507